Drug intelligence / Profile preview

IC84

Development stage: Phase 1
Lead developer: Valneva
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

IC84 is a recombinant protein vaccine candidate developed to prevent disease caused by *Clostridium difficile*. The vaccine consists of two truncated toxins, A and B, from *C. difficile*. These toxins are known to be responsible for disease pathology, and immunity against them can provide protection. IC84 was tested in a Phase I clinical trial with or without the adjuvant aluminum hydroxide to assess its safety and immunogenicity. The developer of this vaccine candidate is Intercell AG.

Other names: Clostridium difficile vaccine - Valneva/GlaxoSmithKlineClostridium difficile vaccine - Valneva/Novartis

Targets

TcdA (Clostridioides difficile toxin A)TcdB (Clostridioides difficile large clostridial toxin family)

Beyond the preview

Go deeper on IC84.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IC84.

Explore the full profile